Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of chemotherapy plus telomerase peptide vaccine (GV1001, RiaVax) as second-line treatment in metastatic colorectal cancer
KCT0003776Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of tertomotide in metastatic colon cancer (mCRC), colon cancer and rectal cancer, sponsored by GemVax & KAEL Co., Ltd. Started Oct 2016; status: completed.
02
Drugs
tertomotide
03
Conditions
metastatic colon cancer (mCRC)colon cancerrectal cancer
Beyond the preview
Go deeper on KCT0003776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003776.